{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T07:07:42Z","timestamp":1765609662359},"reference-count":0,"publisher":"Portland Press Ltd.","issue":"4","content-domain":{"domain":["portlandpress.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[1988,10,1]]},"abstract":"<jats:p>1. Somatostatin analogues, such as SMS 201\u2013995 (sandostatin), have been suggested as treatment for a variety of disease states including acromegaly, secretory gastrointestinal tumours and diabetes mellitus.<\/jats:p>\n               <jats:p>2. Somatostatin-14 has actions to prolong gastrointestinal transit time and inhibit intestinal absorption, and we have therefore studied the effects of SMS 201\u2013995 on these processes. Five male subjects received a test meal having been given either saline or 50 \u03bcg of SMS 201\u2013995 subcutaneously 30 min before ingestion.<\/jats:p>\n               <jats:p>3. SMS 201\u2013995 caused a delay in mouth-to-caecum transit time for lactulose assessed by breath hydrogen analysis (316 \u00b1 17 vs 192 \u00b1 14 min, mean \u00b1sem, P &amp;lt; 0.01), a delay (234 vs 120 min, P &amp;lt; 0.05) in the plasma peak of the non-metabolizable glucose analogue 3-O-methylglucose and conversion of the expected postprandial rise in serum triglycerides (with saline 1.02 \u00b1 0.20 to 1.51 \u00b1 0.28 mmol\/l, P &amp;lt; 0.05) to a decrease below basal values (with SMS 201\u2013995 0.97 \u00b10.80 to 0.79 \u00b1 0.11 mmol\/l, P &amp;lt; 0.05).<\/jats:p>\n               <jats:p>4. After SMS 201\u2013995, an enhancement of the increase in blood glucose (8.2 \u00b10.7 vs 4.7 \u00b10.2 mmol\/l, P &amp;lt; 0.01) and inhibition and postponement of the postprandial rise in insulin (27.6 \u00b16.7 vs 9.9 \u00b12.1 m-units\/l, P &amp;lt; 0.05) occurred. Furthermore, a rise in non-esterified fatty acids, glycerol and 3-hydroxybutyrate, compared with the decline in concentrations of these metabolites after saline, was observed.<\/jats:p>\n               <jats:p>5. We conclude that SMS 201\u2013995 has actions to increase mouth-to-caecum transit time, to diminish the rate of active monosaccharide absorption and to lower basal and postprandial triglyceride levels. These effects probably relate to inhibition of exo- and endo-crine gastrointestinal secretion.<\/jats:p>","DOI":"10.1042\/cs0750345","type":"journal-article","created":{"date-parts":[[2015,8,7]],"date-time":"2015-08-07T11:21:31Z","timestamp":1438946491000},"page":"345-350","update-policy":"http:\/\/dx.doi.org\/10.1042\/crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Effects of the somatostatin analogue SMS 201\u2013995 (sandostatin) on mouth-to-caecum transit time and absorption of fat and carbohydrates in normal man"],"prefix":"10.1042","volume":"75","author":[{"given":"Niels","family":"M\u00f8Ller","sequence":"first","affiliation":[{"name":"Departments of Medicine and Clinical Biochemistry, Royal Victoria Infirmary, Newcastle upon Tyne, U.K."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guyla","family":"Petrany","sequence":"additional","affiliation":[{"name":"Departments of Medicine and Clinical Biochemistry, Royal Victoria Infirmary, Newcastle upon Tyne, U.K."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Cassidy","sequence":"additional","affiliation":[{"name":"Departments of Medicine and Clinical Biochemistry, Royal Victoria Infirmary, Newcastle upon Tyne, U.K."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William L.","family":"Sheldon","sequence":"additional","affiliation":[{"name":"Departments of Medicine and Clinical Biochemistry, Royal Victoria Infirmary, Newcastle upon Tyne, U.K."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Desmond G.","family":"Johnston","sequence":"additional","affiliation":[{"name":"Departments of Medicine and Clinical Biochemistry, Royal Victoria Infirmary, Newcastle upon Tyne, U.K."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael F.","family":"Laker","sequence":"additional","affiliation":[{"name":"Departments of Medicine and Clinical Biochemistry, Royal Victoria Infirmary, Newcastle upon Tyne, U.K."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"288","container-title":["Clinical Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/portlandpress.com\/clinsci\/article-pdf\/75\/4\/345\/459463\/cs0750345.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/portlandpress.com\/clinsci\/article-pdf\/75\/4\/345\/459463\/cs0750345.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T22:26:27Z","timestamp":1638397587000},"score":1,"resource":{"primary":{"URL":"https:\/\/portlandpress.com\/clinsci\/article\/75\/4\/345\/74464\/Effects-of-the-somatostatin-analogue-SMS-201-995"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1988,10,1]]},"references-count":0,"journal-issue":{"issue":"4","published-print":{"date-parts":[[1988,10,1]]}},"URL":"https:\/\/doi.org\/10.1042\/cs0750345","relation":{},"ISSN":["0143-5221","1470-8736"],"issn-type":[{"value":"0143-5221","type":"print"},{"value":"1470-8736","type":"electronic"}],"subject":[],"published":{"date-parts":[[1988,10,1]]}}}